A ten year follow-up after immunization with a two component acellular pertussis vaccine

Pediatric Infectious Disease Journal

Volumn 18, Issue 4, 1999, Pages 361-365

  Tindberg, Ylva ^a   Blennow, Margareta ^a   Granström, Marta ^b  

^a SACHS CHILDREN S HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Acellular pertussis vaccine; Antitoxin; Pertussis; Pertussis toxin

Indexed keywords

PERTUSSIS TOXIN; PERTUSSIS VACCINE;

ANIMAL CELL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BORDETELLA PERTUSSIS; CHILD; CHO CELL; ENDEMIC DISEASE; HUMAN; IMMUNIZATION; INFANT; MAJOR CLINICAL STUDY; NONHUMAN; PERTUSSIS; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032913157     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199904000-00011     Document Type: Article

References (19)

1. Edwards KM. Diphtheria, tetanus and pertussis immunizations in adults. Infect Dis Clin North Am 1990;4:85-103.
2. Wirsing v König, CH, Postels-Multani S, Block HL, Schmitt HJ. Pertussis in adults: frequency of transmission after household exposure. Lancet 1995;346:1326-9.
3. Deen JL, Mink CA, Cherry JD, et al. Household contact study of Bordetella pertussis infections. Clin Infect Dis 1995;21: 1211-9.
4. Simondon F, Preziosi MP, Yam A, et al. A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. Vaccine 1997;15: 1606-12.
5. Storsaeter J, Olin P. Relative efficacy of two acellular pertussis vaccines during three years of passive surveillance. Vaccine 1992;10:142-4.
6. Salmaso S, Mastrantonio P, Wassilak SGF, et al. Persistence of protection through 33 months of age provided by immunization in infancy with two three-component acellular pertussis vaccines. Vaccine 1998;16:1270-5.
7. Tomoda T, Ogura H, Kurashige T. Two primary doses of diphtheria-tetanus-acellular pertussis vaccine induce immunological responses to Bordetella pertussis as strong as those induced by three primary doses. Vaccine 1997;15:1955-8.
8. Blennow M, Granström M, Jäätmaa E, Olin P. Primary immunization of infants with an acellular pertussis vaccine in a double-blind randomized clinical trial. Pediatrics 1988; 82:293-9.
9. Blennow M, Hedenskog S, Granström M. Protective effect of acellular pertussis vaccines. Eur J Clin Microbiol Infect Dis 1988;7:381-3.
10. Blennow M, Granström M. Adverse reactions and serologic response to a booster dose of an acellular pertussis vaccine in children immunized with acellular or whole-cell vaccine. Pediatrics 1989;84:62-7.
11. Blennow M, Granström M. Long term follow-up after pertussis immunization. Pediatr Infect Dis J 1990;9:21-6.
12. Gillenius P, Jäätmaa E, Askelöf P, Granström M, Tiru M. The standardization of an assay for pertussis toxin and antitoxin in microplate culture of Chinese hamster ovary cells. J Biol Stand 1985;13:61-6.
13. Ad Hoc Group for the Study of Pertussis Vaccines. Placebo-controlled trial of two acellular pertussis vaccines in Sweden: protective efficacy and adverse advents. Lancet 1988;1:955-60.
14. Liese JG, Meschievitz CK, Harzer E, et al. Efficacy of a two-component acellular pertussis vaccine in infants. Pediatr Infect Dis J 1997;16:1038-44.
15. Mark A, Granström M. Cumulative incidence of pertussis in an unvaccinated preschool cohort based on notifications, interview and serology. Eur J Epidemiol 1991;7:121-6.
16. Isacson J, Trollfors B, Taranger J, et al. How common is whooping cough in a nonvaccinating country? Pediatr Infect Dis J 1993;12:288-92.
17. Blennow M, Olin P, Granström M, Bernier RH. Protective efficacy of a whole-cell pertussis vaccine. Br Med J 1988;296: 1570-2.
18. Carlsson RM, Claesson B, Selstam U, et al. Safety and immunogenicity of a combined diphtheria-tetanus-acellular pertussis-inactivated polio vaccine-Haemophilus influenzae type b vaccine administered at 2-4-6-13 or 3-5-12 months of age. Pediatr Infect Dis J 1998;17:1026-33.
19. Olin P, Rasmussen F, Gustafsson L, Hallander HO, Heijbel H. Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Lancet 1997;350: 1569-77.